Successful pre‐implantation genetic diagnosis for Hirschsprung disease
P. Burlet,C. Steichen,L. Hesters,N. Gigarel,V. Kerbrat,René Frydman,A. Munnich,J. Amiel,N. Frydman,J. Steffann
DOI: https://doi.org/10.1111/j.1399-0004.2011.01634.x
2011-10-01
Clinical Genetics
Abstract:To the Editor : Hirschsprung disease (HSCR, OMIM142623) is the consequence of a lack of neurons in the myenteric and submucosal plexuses along a variable length of the intestine. In isolated (non-syndromic) HSCR, the recurrence risk in the sibship of the index case varies from 1% to 33%, taking into account (i) the gender and the length of the aganglionic segment of the index case and (ii) the gender of the sib (1, 2). HSCR is genetically heterogeneous, mutations being identified in 11 genes thus far (3). The major susceptibility gene is RET (OMIM164761), which encodes a receptor tyrosine kinase (4). RET mutations are identified in about 50% of familial cases, offering to these families the possibility to perform prenatal diagnosis (PND) or pre-implantation genetic diagnosis (PGD). Such procedures remain however controversial, due to the incomplete sex-dependent penetrance of RET mutations (50% and 70% in females and males, respectively) (2, 5), and because this disorder is curable by surgical procedures. A couple was referred to our PGD center because the male partner and his two children suffered from severe HSCR caused by a RET exon 4 mutation (c.751insGC). Despite surgery undertook in the neonatal period, the son suffered from constipation requiring daily laxatives or enemas, and the 6-year-old daughter still complained of soiling. This couple experienced PND and terminated the pregnancy of a carrier fetus. The PGD test was developed on 50 heterozygous lymphocytes by coamplification of the c.751insGC RET mutation with a polymorphic marker located in intron 5 of the RET gene, using multiplex nested polymerase chain reaction (PCR) (Table 1) (6). Amplification failure and allele drop-out rates were respectively of 5% and 8% for the RET mutation, and 4% and 2% for the intron 5 marker. No contamination was detected. The couple underwent one treatment cycle, 17 oocytes were sampled, of whom 13 fertilized (76%), resulting in four embryos at day 3. Conclusive results were obtained for three of the four embryos (Fig. 1). All embryos were diagnosed to be unaffected, and two were transferred on day 5, resulting in a twin pregnancy, and the birth of two healthy boys. Pre-implantation diagnosis was confirmed on cord blood DNA. The use of PGD for other purpose than serious heritable disorders raises ethical and legal discussions (7, 8). French Law links the practice of PGD to PND, stipulating that PGD must be carried out inside a multidisciplinary network licensed for PND and supervised by the French Biomedicine Agency. Access to these procedures is indeed limited to couple being at high risk of giving birth to a child affected with a serious genetic disease, incurable at the time of the diagnosis. In this respect, PGD for HSCR has been considered as questionable. First, surgery can cure the disease. Surgical therapies are however associated with an unsatisfactory long-term prognosis for many (9, 10).